Healing & Recovery Peptides

Healing and recovery peptides represent one of the most active areas of preclinical peptide research. These compounds target the biological machinery of tissue repair — angiogenesis, cell migration, collagen remodelling, and inflammation resolution — to accelerate healing after injury or surgery. Unlike conventional anti-inflammatories that suppress the healing cascade, these peptides work with the body's own repair systems to support faster and more complete recovery.

BPC-157 (Body Protection Compound 157) is the cornerstone of this category. A synthetic pentadecapeptide derived from a naturally occurring gastric protein, BPC-157 has demonstrated remarkable tissue-repair properties across a wide range of preclinical models — including tendon, ligament, muscle, bone, and gut. It promotes angiogenesis (new blood vessel formation), upregulates growth factor receptors, and modulates the nitric oxide system to accelerate healing in multiple tissue types simultaneously.

TB-500 (Thymosin Beta-4) complements BPC-157 through a different mechanism. It promotes actin polymerisation, which is fundamental to cell structure and motility. By upregulating actin, TB-500 enhances the migration of repair cells — fibroblasts, endothelial cells, and keratinocytes — to the site of injury. The BPC-157 + TB-500 combination is heavily marketed online, but no controlled human trials of the combination exist. See our independent claim review for this combination before considering the marketing claims at face value.

GHK-Cu (copper tripeptide-1) brings a third dimension to healing. This naturally occurring copper-binding peptide is found in blood plasma, saliva, and urine, and concentrations decline significantly with age. GHK-Cu promotes collagen synthesis, upregulates antioxidant defences, and has been shown to reset over 4,000 human genes toward a younger expression profile. In the context of healing, it improves tissue quality and skin integrity alongside the structural repair driven by BPC-157 and TB-500.

In the UK, these peptides are unregulated research chemicals and are not approved as medicines by the MHRA. They cannot lawfully be marketed for human use. Researchers and clinicians interested in these compounds should consult the MHRA's guidance on unlicensed medicines and engage with qualified medical professionals before any clinical application. The preclinical evidence base is substantial, but human trial data remains limited.

Related research areas include joint health, sports medicine recovery, gut mucosal healing, wound care, and post-surgical recovery. Online sources frequently propose combinations with GH secretagogues (ipamorelin, CJC-1295) or immune-modulators (thymosin alpha-1) as "comprehensive recovery protocols", but these combinations have no controlled human trial evidence and Peptide Authority does not publish stacking protocols. See our no-dosing-no-sourcing policy.